Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:182-189
Published online before print October 26, 2006, doi: 10.1161/01.ATV.0000251021.28725.e8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/1/182    most recent
01.ATV.0000251021.28725.e8v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joner, M.
Right arrow Articles by Virmani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joner, M.
Right arrow Articles by Virmani, R.
Related Collections
Right arrow Catheter-based coronary interventions: stents
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:182.)
© 2007 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-ß and MCP-1

Michael Joner; Andrew Farb; Qi Cheng; Aloke V. Finn; Eduardo Acampado; Allen P. Burke; Kristi Skorija; Wendy Creighton; Frank D. Kolodgie; Herman K. Gold; Renu Virmani

From CVPath Institute Inc (M.J., Q.C., F.D.K., E.A., A.P.B., W.C., K.S., R.V.), Gaithersburg, Md; the Center for Devices and Radiological Health, U.S. Food and Drug Administration (A.F.), Rockville, Md; Cardiac Unit (A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass.

Correspondence to Renu Virmani, MD, Medical Director, CVPath, International Registry of Pathology, 19 Firstfield, Road, Gaithersburg, MD 20878. E-mail rvirmani{at}cvpath.org

Objective— Although emerging data from preclinical and clinical studies suggests a reduction of in-stent restenosis with peroxisome proliferator-activated receptor (PPAR)-{gamma} agonists, the reduction of neointimal growth via anti-inflammatory mechanisms has not been explored.

Methods and Results— Hypercholesterolemic New Zealand White rabbits (n=45) received bilateral balloon-expandable stents implanted into atherosclerotic iliac arteries. Animals were randomized to oral pioglitazone 3 (low dose) or 10 mg/kg per day (high dose) started on the day of stent implantation; control rabbits received placebo. Tissue harvest was performed 28 days after stenting, and stented segments underwent histology, morphometry, immunostaining for macrophages, and scanning electron microscopy. In selected animals, stented arterial segments were placed in organoid culture for 48 hours, and the conditioned media was assayed for 23 different cytokines. There was a 21% reduction in neointimal area for high-dose pioglitazone treated versus placebo rabbits (P<0.005), which was associated with a significant reduction of neointimal macrophages. Analysis of conditioned media revealed an 82% and 74% reduction in the release of monocyte chemoattractant protein-1 (MCP-1) (P<0.007) and transforming growth factor (TGF)-ß1 (P<0.01), respectively, in stented segments from animals treated with 10 mg/kg per day pioglitazone versus placebo.

Conclusions— Oral pioglitazone suppresses in-stent neointimal growth by limiting local inflammatory pathways and may be useful as an adjunctive therapy in patients undergoing percutaneous interventions.

Although emerging data from preclinical and clinical studies suggests a reduction of in-stent restenosis with peroxisome proliferator-activated receptor (PPAR)-{gamma} agonists, the reduction of neointimal growth via anti-inflammatory mechanisms have not been explored. Oral pioglitazone suppresses in-stent neointimal growth by limiting local inflammatory pathways and may be useful as an adjunctive therapy in patients undergoing percutaneous interventions.


Key Words: inflammation • pioglitazone • rabbit • restenosis • stent




This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. Tanaka, T. Hasegawa, Z. Chen, Y. Okita, and K. Okada
Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation
J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 744 - 751.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al.
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 524 - 531.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han
Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone
Am. J. Pathol., June 1, 2009; 174(6): 2007 - 2014.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
F. Montecucco and F. Mach
Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis
Rheumatology, January 1, 2009; 48(1): 11 - 22.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Joner, K. Morimoto, H. Kasukawa, K. Steigerwald, S. Merl, G. Nakazawa, M. C. John, A. V. Finn, E. Acampado, F. D. Kolodgie, et al.
Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1960 - 1966.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Ibanez, G. Vilahur, G. Cimmino, W. S. Speidl, A. Pinero, B. G. Choi, M. U. Zafar, C. G. Santos-Gallego, B. Krause, L. Badimon, et al.
Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1104 - 1109.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Nakamura, E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama
Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan
Hypertension, February 1, 2008; 51(2): 296 - 301.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. F. Luscher, J. Steffel, F. R. Eberli, M. Joner, G. Nakazawa, F. C. Tanner, and R. Virmani
Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications
Circulation, February 27, 2007; 115(8): 1051 - 1058.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]